what’s the price target on this rationally though? Tom sounds frustrated about share price ceiling - which we all share - but catalysts now are few. No re-rate and it’s bleeding.
Its quoted above as upon regulatory success the payout is “enormous” - But, realistically where does that stand.
I’m a holder with conviction and have a decent packet of shares but im interested in peoples thoughts on price target. Me personally with FDA and EMA TAM my calculation was about 2.50 upon regulatory success + premium on top of sale of asset upon but that’s very rough.
interested in your thoughts.
Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-151
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.411M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 158 | 7.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 5000 | 1 |
View Market Depth
| Last trade - 16.12pm 29/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable